A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT04792489

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-25T22:27:52.907953+00:00

Published At

2025-04-24T00:00:00+00:00

Record Updated At

2025-04-24

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Refractory Diffuse Large B Cell Lymphoma (DLBCL)", "Relapsed Diffuse Large B Cell Lymphoma", "High Grade B-cell Lymphoma (HGBCL)", "Primary Mediastinal B-cell Lymphoma (PMBCL)", "Transformed Lymphoma", "Central Nervous System Lymphoma", "Mantle Cell Lymphoma (MCL)", "Richter Transformation"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2025-04-24"

protocolSection.identificationModule.nctId

"NCT04792489"

protocolSection.identificationModule.officialTitle

"A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Refractory Diffuse Large B Cell Lymphoma (DLBCL) (protocolSection.conditionsModule.conditions)
• Relapsed Diffuse Large B Cell Lymphoma (protocolSection.conditionsModule.conditions)
• High Grade B-cell Lymphoma (HGBCL) (protocolSection.conditionsModule.conditions)
• Primary Mediastinal B-cell Lymphoma (PMBCL) (protocolSection.conditionsModule.conditions)
• Transformed Lymphoma (protocolSection.conditionsModule.conditions)
• Central Nervous System Lymphoma (protocolSection.conditionsModule.conditions)
• Mantle Cell Lymphoma (MCL) (protocolSection.conditionsModule.conditions)
• Richter Transformation (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.